Topic Listing for ONYX Pharmaceuticals

Accounting Firm Accounting Pronouncements Affect Future Financial Position Results Operations
Administration Aggregated Option Exercises Last End Values
Amendments Employment Agreement Compensation Package Annual Incentive Bonus Program
Anthony Coles Approval Amendment 1996 Employee Stock Purchase Plan
Approval Amendment 2005 Equity Incentive Plan Approval Amendment Employee Stock Purchase Plan
Audit Committee Available Information
Awards Granted 2008 Incentive Plan Base Salary
Base Salary Annual Incentive Bonus Program Bayer
Bayer Pharmaceuticals Corporation Bayers Business Strategy Changes Adversely Affect Collaborative Relationship
Beneficial Owner Shares Registered Name Broker Bank Beneficial Ownership Reporting Compliance
Benefits Perquisites Board Directors Recommends Vote Favor Proposal
Board Directors Recommends Vote Proposals Identified Above Breast Cancer Program
Btg Cash Equivalents Marketable Securities
Cell Cycle Program Certain Tax Considerations
Certain Transactions Change Control Payment Benefit Estimates 2006
Change Vote After Submitting Proxy Changes Capital Structure
Changes Capitalization Changes Internal Control Over Financial Reporting
Chief Executive Officer Compensation Clinical Trials
Clinical Trials Fail Demonstrate Nexavar Safe Effective Cancer Clinical Trials Take Longer Complete Project Not Completed
Code Conduct Code Ethics
Coles Change-in-control Severance Agreement Coles Severance Arrangement
Collaboration Agreements Collaboration Bayer
Collaborations Commercialization Status
Comparison Cumulative Total Return Compensation Benchmarking
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Directors Compensation Discussion Analysis
Compensation Objectives Compensation Philosophy
Competing Therapies Approved Treatment Advanced Kidney Cancer Expect Competition
Comprehensive Loss Concentration Credit Risk
Concentration Credit Risk Significant Research Development Collaborators Contingencies
Contractual Obligations Commitments Corporate Governance
Corporate Transactions Corporate Transactions Changes Control
Critical Accounting Policies Estimates Dependent Collaborative Relationship Bayer Manufacture Further Develop Commercialize
Dependent Efforts Bayer Market Promote Nexavar Dependent Efforts Bayer Market Promote Nexavar Countries Outside
Development Strategy Did Receive Full Set Proxy Materials Instead Notice
Did Receive Notice Regarding Internet Availability Proxy Materials Didnt Receive Notice Internet Availability Proxy Materials
Director Compensation Director Compensation 2006
Director Compensation 2007 Directors Continuing Office Until 2006 Annual Meeting Class
Directors Continuing Office Until 2007 Annual Meeting Class Directors Continuing Office Until 2008 Annual Meeting Class
Directors Continuing Office Until 2009 Annual Meeting Class Directors Continuing Office Until 2010 Annual Meeting Class
Directors Continuing Office Until 2011 Annual Meeting Class Dividends
Documents Incorporated Reference Duration Termination Amendment
Earlier Stage Clinical Development Effect Certain Corporate Transactions
Election Directors Eligibility
Employees Employment Severance Change Control Agreements
Equity Compensation Equity Grant Practices
Equity Incentive Compensation Estimates
Evaluation Disclosure Controls Procedures Even Though Stopped Phase Liver Cancer Trial Nexavar
Exact Name Registrant Specified Charter Executive Change-in-control Severance Benefits Agreement
Executive Compensation Components Executive Compensation Philosophy Objectives
Executive Compensation Summary Executive Equity Compensation
Executive Officer Compensation Executive Severance Benefit Plan
Existing Stockholders Significant Influence Over Face Intense Competition Rapid Technological Change Competitors Substantially
Face Product Liability Risks Not Able Obtain Adequate Fair Values Financial Instruments
Federal Income Tax Information Financial Statement Schedules
Find Out Results Voting Annual Meeting Form 10-k
General General Administrative Expenses
Government Regulation Gregory Schafer
Guarantees Indemnifications Guarantees Indemnifications Contingencies
Held 2006 Held 2007
Held 2008 Henry Fuchs
History Losses Expect Continue Incur Holders
Hollings Renton Householding Proxy Materials
Http Wwwonyx-pharmcom Impact Adoption Fas 123
Impairment Long-lived Assets Important Notice Regarding Availability Proxy Materials Stockholders Meeting
Including Area Code Registrants Principal Executive Offices Income Taxes
Incur Significant Liability Determined Promoting Off-label Drugs Otherwise Independence Board Directors
Index Financial Statements Information
Information Concerning Solicitation Voting Information Regarding Board Directors Committees
Inherent Limitations Effectiveness Controls Interest Income Expense Net
Interest Rate Risk Judy Batlin
Juergen Lasowski Phd Kidney Cancer Program
Licensed Product Candidates Licensing Agreement Btg
Liquidity Capital Resources Liver Cancer Program
Lose Key Employees Consultants Unable Attract Retain Qualified Lung Cancer Program
Management Managements Report Internal Control Over Financial Reporting
Manufacturing Market Not Accept Products Pharmaceutical Pricing Reimbursement Pressures
Marketing Expenses Marketing Sales
Matthew Fust Meetings Board Directors
Metastatic Melanoma Program Narrative Summary Compensation Table Grants Plan-based Awards
Need Substantial Additional Funds Future Access Capital Uncertain Net Expense Due Unconsolidated Joint Business
Net Expense Unconsolidated Joint Business Net Income Loss Per Share
Net Loss Per Share New Plan Benefits
New Plan Benefits Amendment Nexavar
Nominating Corporate Governance Committee Nominating Governance Committee
Nominees Election Term Expiring 2010 Annual Meeting Class Nominees Election Term Expiring 2011 Annual Meeting Class
Nominees Election Term Expiring 2012 Annual Meeting Class Nominees Election Three-year Term Expiring 2008 Annual Meeting
Nominees Election Three-year Term Expiring 2009 Annual Meeting Non-discretionary Grant Program
Non-employee Director Compensation Table 2005 Not Able Protect Intellectual Property Operate Business Without
Not Manufacturing Expertise Capabilities Dependent Bayer Fulfill Needs Not Receive Timely Accurate Financial Market Information Bayer
Notice Annual Meeting Stockholders Held 2009 Offering Periods
Onx 0801 Onx 0803 0805
Onyx Pharmaceuticals Inc Operating Results Unpredictable Fluctuate Below Expectations Securities Analysts
Option Agreement Sbio Option Grants Last
Other Expense Related Party Other Income
Other Long-term Assets Other Matters
Overview Part
Partial List Potentially Competing Agents Participation Plan
Patents Proprietary Rights Paying Proxy Solicitation
Payment Purchase Price Payroll Deductions Performance Measurement Comparison
Performance-based Cash Bonus Phase
Phase Combination Chemotherapies Multiple Tumor Types Phase Kidney Cancer
Phase Multiple Tumor Types Post-employment Obligations
Potential Post-employment Payments Powell Street Emeryville California 94608 510 597-6500
Power Attorney Pre-approval Policies Procedures
Preferred Stock Principal Accountant Fees Services
Pro Forma Information Periods Prior Adoption Fas 123 Process Setting Executive Officer Performance Compensation
Product Candidates Property Equipment
Proposal Proposal Approval 2005 Equity Incentive Plan
Proposal Approval Increase Number Authorized Shares Common Stock Proposal Election Directors
Provisions Collaboration Agreement Bayer Prevent Delay Change Control Provisions Delaware Law Charter Executive Change Control Agreements
Purchase Price Purchase Stock
Purpose Ratification Selection Independent Registered Public Accounting Firm
Receiving Materials Recent Sales Unregistered Securities
Recently Issued Accounting Standard Recently Issued Accounting Standards
Related Party Transactions Related-person Transactions Policy Procedures
Report Audit Committee Board Directors Report Compensation Committee
Report Independent Registered Public Accounting Firm Research Development
Research Development Expense Research Development Expenses
Restrictions Transfer Restructuring
Revenue Collaboration Agreement Revenue Recognition
Risk Securities Class Action Litigation Due Expected Stock Role Compensation Committee
Sbio Securities Authorized Issuance Equity Compensation
Securities Authorized Issuance Equity Compensation Plans Securities Authorized Issuance Equity Compensation Plans 2004
Securities Authorized Issuance Equity Compensation Plans 2006 Securities Authorized Issuance Equity Compensation Plans 2007
Securities Authorized Issuance Equity Compensation Plans 2008 Securities Registered Pursuant Act
Security Ownership Certain Beneficial Owners Management Segment Reporting
Separation Agreements Serious Adverse Side Effects Associated Nexavar Approval Revoked
Signatures Specialty Pharmacies Distributors Bayer Rely Sell Products Fail
Statements Operations Stock Based Compensation
Stock Option Grants Exercises Stock Options Employee Purchase Plan
Stock Performance Graph Stock Price Volatile
Stock Subject 2005 Incentive Plan Stock Subject Incentive Plan
Stock Subject Purchase Plan Stock-based Compensation
Stockholder Communications Board Directors Stockholder Proposals Due Next Annual Meeting
Stockholder Record Shares Registered Name Subject Extensive Government Regulation Costly Time Consuming Unanticipated
Summary Compensation Table Contents
Target Pay Position Mix Tax Considerations
Termination Amendment Termination Employment
Terms Options Terms Other Stock Awards
Terms Performance Awards Terms Stock Appreciation Rights
Terms Stock Bonus Awards Terms Stock Purchase Awards Bonus
Terms Stock Unit Awards Total Compensation
Total Revenue Valuation Assumptions
Virus Platform Vote
Vote Annual Meeting Vote Favor Proposal
Vote Proxy Over Internet Telephone Vote Shares Filling Out Returning Notice
Votes Votes Counted
Votes Needed Approve Each Proposal Warner-lambert
Warrants Washington 20549
What Mean Receive Proxy Card What Quorum Requirement
What Return Proxy Card Not Make Specific Choices What Voting
While Nexavar Received Approvals Sale Several Countries Outside Withdrawal
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki